AstraZeneca Showcases Oncology Breakthroughs at ASCO 2025, Reinforcing Mission to Eliminate Cancer as a Cause of Death
AstraZeneca will present new data from over 80 abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 – June 3), underscoring its leadership in oncology through a diverse and robust pipeline. The presentations span 20 approved and investigational therapies, including two plenary sessions, one special late-breaking oral abstract, and 19 additional oral presentations.
Key Highlights
Breast Cancer
- SERENA-6 (Plenary #LBA4): The first positive Phase III trial for camizestrant, a next-generation oral SERD, in combination with CDK4/6 inhibitors in HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations. The trial is pioneering the use of circulating tumor DNA (ctDNA) to guide treatment in a first-line setting.
- DESTINY-Breast09 (Oral Abstract #LBA1008): Interim Phase III results for Enhertu (trastuzumab deruxtecan) combined with pertuzumab showed superiority over standard-of-care in HER2-positive metastatic breast cancer—the first such advancement in over a decade.
Gastric & Gastroesophageal Junction Cancers
- MATTERHORN (Plenary #LBA5): Perioperative use of Imfinzi (durvalumab) with FLOT chemotherapy demonstrated event-free survival benefits in resectable gastric and GEJ cancers.
Lung Cancer
- NeoADAURA (Oral Abstract #8001): Neoadjuvant Tagrisso (osimertinib), with or without chemotherapy, improved outcomes in early-stage EGFR-mutated NSCLC.
- TROPION-Lung02 (Oral Abstract #8501): Biomarker analyses of Datopotamab deruxtecan plus pembrolizumab, with or without platinum chemotherapy, in first-line advanced NSCLC patients without actionable mutations.
Other Notable Studies
- DESTINY-Gastric04 (Oral Abstract #LBA4002): Enhertu outperformed ramucirumab + paclitaxel in second-line HER2-positive metastatic gastric/GEJ cancer.
- KOMET (Rapid Oral Abstract #3014): Koselugo (selumetinib) showed efficacy in adults with NF1 and symptomatic, inoperable plexiform neurofibromas.
Executive Commentary
Susan Galbraith, EVP, Oncology R&D, noted:
“Our presentations, particularly SERENA-6 and DESTINY-Breast09, represent transformative innovations. SERENA-6 is the first to integrate ctDNA-guided therapy in first-line breast cancer treatment, while DESTINY-Breast09 redefines HER2-positive metastatic care.”
Dave Fredrickson, EVP, Oncology Business Unit, added:
“MATTERHORN exemplifies our strategy to bring immunotherapies into earlier cancer stages with curative intent. Featuring in ASCO plenary sessions for a seventh consecutive year reflects the depth and impact of our pipeline.”
Collaborations
- Enhertu and Datopotamab deruxtecan are developed with Daiichi Sankyo.
- Koselugo is co-developed with MSD (Merck & Co., Inc.).
- Orpathys (savolitinib) is developed in partnership with HUTCHMED.
Select Presentation Highlights at ASCO 2025
| Therapy Area | Study | Abstract # | Presentation Type | Date/Time (CDT) |
|---|---|---|---|---|
| Breast Cancer | SERENA-6 | LBA4 | Plenary | June 1, 2:41pm |
| Breast Cancer | DESTINY-Breast09 | LBA1008 | Oral | June 2, 7:30am |
| Gastric/GEJ Cancer | MATTERHORN | LBA5 | Plenary | June 1, 3:13pm |
| Gastric/GEJ Cancer | DESTINY-Gastric04 | LBA4002 | Oral | May 31, 3:24pm |
| NSCLC | NeoADAURA | 8001 | Oral | June 2, 3:12pm |
| NSCLC | TROPION-Lung02 | 8501 | Oral | June 1, 8:12am |
| Rare Disease | KOMET | 3014 | Rapid Oral | June 2, 8:00am |
This expansive and diverse data set affirms AstraZeneca’s commitment to advancing science and transforming patient outcomes across multiple cancer types.
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
